We also observed higher CD137 expression in M0 and CCL17hi M2, but not in IL12hi M1 cells, indicating that increased expression of CD137 on tumor-infiltrating cells is associated with improved response to anti-PD-1 treatment, but this may be specific to certain cancer types. The gene discussed is TNFRSF9; the disease is neoplasm.